QualityCounts.com  
Home iHerb Int Antiaging Sys LEF at Amazon LEF at LEF Amazon.com Contact
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:
 iHerb
 Int. Anti-aging Systems
 Puritan's Pride
 Vitamin Shoppe
 Vital Choice Seafood
 
Please support this website by purchasing via the links on the website.

Home > Health Conditions > Diabetes > Onglyza (saxagliptin)

Onglyza (saxagliptin)

Related Topics:

News & Research:

  • FDA Warns of Heart Failure Risk With Two Diabetes Drugs - Medscape, 4/5/16 - "Health care professionals should consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure and monitor their diabetes control ... In the saxagliptin trial, which included 16,492 patients with type 2 diabetes and established cardiovascular disease or who were at high risk for cardiovascular disease, there was no overall risk for cardiovascular events, but there was a 27% increase (3.5% vs. 2.8%) in the rate of the first event of hospitalization for heart failure and a potential increased risk for all-cause mortality"
  • Metformin vs. Sulfonylureas for Diabetes - WebMD, 12/4/09 - "Researchers reported that diabetes patients who used sulfonylureas had a higher risk of death from all causes and a higher risk of heart failure than diabetes patients who used the most widely prescribed diabetes drug, metformin ... Compared with metformin, also known as Glucophage, single-drug treatment with first- and second-generation sulfonylureas was associated with up to a 61% increased risk for death. Users of second-generation sulfonylureas had up to a 30% higher risk for congestive heart failure ... Patients treated with Actos or Avandia did not appear to have a greater risk for heart attacks than those treated with metformin"
  • FDA Approves Saxagliptin for Type 2 Diabetes - Doctor's Guide, 7/31/09 - "Although saxagliptin was not associated with an increased risk for cardiovascular events in patients who were mainly at low risk for these events, the FDA is requiring a post-market study that will specifically evaluate cardiovascular safety in a higher risk population"

Related Searches:

70526

  QualityCounts.com Anti-aging Newsletter
Newsletter Sign-up
Add to Netvibes

Netvibes basic (free)

Join QualityCounts.com on Facebook